In conclusion, we found that JAM-A can be regarded as a potential target in ESCC and designed a method for producing a high affinity mAb 61H9G4 against JAM-A, which can inhibit the growth of ESCC in vitro and vivo. The gene discussed is F11R; the disease is esophageal squamous cell carcinoma.